MatchMedi
한국어

Patient pathway

My doctor gave several options

A pathway for comparing categories without turning the site into a recommender.

What this situation means

  • Different doctors may emphasize surgery, immunotherapy, targeted therapy, trials, local therapy, or supportive care based on different risks and goals.

What not to assume

  • Do not assume disagreement means one doctor is wrong; ask what facts each option depends on.

Information to gather

  • Option list
  • stated goal of each option
  • timing constraints
  • what would make each option stop

Bring to the surgeon

  • What local-control problem are we solving?

Bring to the oncologist

  • What is the goal of each option?
  • What happens if it works briefly?
  • What option would become harder if we start now?

Bring to the trial team

  • Would this option change trial fit or timing?

Related database records

Related treatment pages

clinical-trial

Clinical trials in melanoma

Trial listings can show studies that mention a cancer, mutation, drug, or treatment history, but a listing match does not mean a study fits.

immunotherapy

Immune checkpoint inhibitors

Immunotherapy can help the immune system recognize and attack melanoma, but it can also cause immune-related side effects.

Related trial leads

A trial record is a lead only. The trial team must confirm whether it fits.

Phase 1/2 · completed

NCT03973151

Primary early clinical trial record for HL-085/tunlametinib in NRAS-mutant advanced melanoma.

This record is not the exact tunlametinib plus nivolumab combination remembered by the user.

Phase 3 · recruiting

NCT06008106

Phase III comparator trial after prior immunotherapy; useful for duration-of-response and trial-timing questions.

A trial listing match does not mean the trial fits. The trial team must confirm.

Phase 1 · unknown

NCT04835805

A sourced NRAS melanoma trial lead after anti-PD-1/PD-L1 therapy that may explain a remembered MEK/RAF plus PD-1 trial concept.

This is belvarafenib/cobimetinib/nivolumab, not tunlametinib/nivolumab.

Phase 1/2 · completed

NCT03979651

NRAS melanoma research lead involving MEK inhibition and autophagy inhibition.

Trial record does not make this a routine treatment option.

Related cohort threads

Sources with the medical details

  1. ClinicalTrials.gov API. Accessed 2026-05-20.
  2. NCI Clinical Trials Search API. Accessed 2026-05-20.
  3. Melanoma Treatment (PDQ) - Patient Version. Accessed 2026-05-20.
  4. NCT06008106: Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma. Accessed 2026-05-20.
  5. Drugs Approved for Melanoma. Accessed 2026-05-20.